Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siliankang dose-ranging phase 2 trial in children with acute diarrhea
ChiCTR2500102335Phase 2Completed
- Sponsor
- Beijing Children's Hospital
- Start
- May 2025
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Bifidobacterium tetravaccine in acute diarrhea (4 arms), sponsored by Beijing Children's Hospital. Primary endpoint: Rate of diarrhea resolution within 72 hours after study drug administration. Started May 2025; status: completed.
02
Drugs
Bifidobacterium tetravaccine
03
Conditions
acute diarrhea
Beyond the preview
Go deeper on ChiCTR2500102335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102335.